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Abstract
Colorectal cancer (CRC) is the third most common cancer disease in the Western world, and about 40% of the
patients die from this disease. The cancer cells are commonly genetically unstable, but only a few low-frequency
recurrent fusion genes have so far been reported for this disease. In this study, we present a thorough search for
novel fusion transcripts in CRC using high-throughput RNA sequencing. From altogether 220 million paired-end
sequence reads from seven CRC cell lines, we identified 3391 candidate fused transcripts. By stringent require-
ments, we nominated 11 candidate fusion transcripts for further experimental validation, of which 10 were positive
by reverse transcription–polymerase chain reaction and Sanger sequencing. Six were intrachromosomal fusion tran-
scripts, and interestingly, three of these, AKAP13-PDE8A, COMMD10-AP3S1, and CTB-35F21.1-PSD2, were present
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in, respectively, 18, 18, and 20 of 21 analyzed cell lines and in, respectively, 18, 61, and 48 (17%-58%) of 106 primary
cancer tissues. These three fusion transcripts were also detected in 2 to 4 of 14 normal colonic mucosa samples
(14%-28%). Whole-genome sequencing identified a specific genomic breakpoint in COMMD10-AP3S1 and further
indicates that both the COMMD10-AP3S1 and AKAP13-PDE8A fusion transcripts are due to genomic duplications in
specific cell lines. In conclusion, we have identified AKAP13-PDE8A, COMMD10-AP3S1, and CTB-35F21.1-PSD2 as
novel intrachromosomal fusion transcripts and the most highly recurring chimeric transcripts described for CRC to
date. The functional and clinical relevance of these chimeric RNA molecules remains to be elucidated.
Translational Oncology (2013) 6, 546–553
Introduction
Colorectal cancer (CRC) is a global health problem with a high in-
cidence and mortality. It is the second most common cancer type in
Europe, and only lung cancer causes more cancer deaths per year [1].
The management of CRC is therefore in need of improved biomarkers
for detection, monitoring, and prognostication, as well as prediction
of treatment response [2]. Furthermore, effective targeted therapies
are warranted for this disease [3]. A promising strategy to meet these
demands is to identify highly cancer-specific molecules.
Gene expression profiling has been used to identify genes with ec-
topic expression in cancer. However, the efforts so far have not been
sufficient for development of any differentially expressed genes into
clinically useful biomarkers, probably because the gene expression is
not specific enough for the malignant cells. Differential pre-mRNA
processing adds an additional layer of complexity, and dysregulation
of alternative splicing and promoter switches may yield cancer-specific
transcripts and protein isoforms [4]. Chimeric fusion transcripts rep-
resent another source of common cancer-specific RNA and proteins
and have, for other cancer types, been useful in both cancer detection
and monitoring of patients with cancer, as well as being direct targets
for treatment. Most recurrent fusion genes previously identified have
been found from studies of hematological malignancies and sarcomas.
Among the four most common carcinomas, the surprising discovery of
the TMPRSS2-ERG fusion gene present in about half of all prostate
cancers was reported in 2005 [5]. Later, several additional recurrent
fusion genes in prostate cancer have been reported [6–10]. Further-
more, but with lower frequencies, fusion genes involving the targetable
ALK, ROS1, and RET partners have been found in lung cancer [11–14].
In breast cancer, a recurrent fusion with a low frequency, SEC16A-
NOTCH1, has been reported [15]. For CRC, there are three recent
reports of recurrent fusion transcripts [13,16,17], but all of them occur
in low frequencies.
Fusion transcripts are often produced after chromosomal rearrange-
ments but can also be generated by RNA polymerase read-throughs
and trans-splicing of pre-mRNA. Recently, there have been reports that
chimeric fusion transcripts, generated by polymerase read-throughs and
trans-splicing, are common within prostate cancers [18,19]. Low, but
detectable, levels of SLC45A3-ELK4 mRNA was found in both benign
and malignant prostate tissues, with higher expression of the fusion tran-
script in the malignant tissues [9]. Interestingly, there is also evidence for
chimeric transcripts to be frequent and nonrandomwithin nonmalignant
cells [20], and protein products from chimeric transcripts were recently
reported to be commonly present in human cells [21]. Chimeric tran-
scripts were recently also shown to have a regulatory role of growth in
cancer cells [22]. The recent ENCODE transcriptome study suggests
that the definition of a gene should be redefined on the basis of their
findings of widespread overlapping of neighboring gene regions [23].
Furthermore, presence of fusion transcripts in nonmalignant cells,
generated by trans-splicing, has been demonstrated to guide chromo-
somal rearrangements involving the same fusion partners in endo-
metrial stromal tumors [24]. Regardless of the mechanisms, fusion
transcripts may encode cancer-specific chimeric proteins, which are
promising as biomarkers and also as targets for therapy.
Identification of recurrent fusion transcripts in CRC may aid the
development of improved diagnostics and tailored treatment. In this
study, we have identified novel fusion transcripts from colon cancer
cell lines by use of paired-end RNA sequencing and shown their
presence also in malignant, and sometimes nonmalignant, tissue
from the large bowel.
Methods
Colon Cancer Cell Lines and Clinical Tissue Samples
Seven colon cancer cell lines were included in the RNA sequencing
analyses. HCT15, SW48, HCT116, and RKO are known to be of the
microsatellite instability (MSI) phenotype, and HT29, SW480, and
LS1034 are microsatellite stable (MSS) [25]. Fourteen additional
colon cancer cell lines were added to the validation panel (SW620,
LoVo, Co115, Colo320, IS1, IS2, IS3, TC7, TC71, FRI, V9P,
LS174T, EB, and NCI-H508). The cell lines have been obtained
from Dr Richard Hamelin (INSERM, Paris, France) and American
Type Culture Collection (Manassas, VA). Culturing conditions for
the individual cell lines will be given on request. The cell lines have pre-
viously been karyotyped, and copy number was assessed by comparative
genomic hybridization (CGH). Identities of the cell lines were verified
by the AmpFlSTR Identifiler PCR Amplification Kit (Applied Bio-
systems by Life Technologies, Carlsbad, CA). Cell lines were harvested
at a time point shortly before confluence was reached, and RNA
was isolated using TRIzol (Life Technologies Inc, Rockville, MD).
Quantity was measured using NanoDrop ND-1000 (Thermo Fisher
Scientific, Waltham, MA), and quality was evaluated with Agilent
2100 BioAnalyzer (Agilent Technologies, Santa Clara, CA).
Tissue samples were collected from 106 patients treated surgically
for CRC in hospitals in the Oslo region, Norway. The CRCs were
enriched for clinical stages II and III (52 stage II, 53 stage III, and
1 stage IV CRCs) and included both MSI and MSS types [n = 20 and
85 (one sample not scored), respectively]. A summary of clinical data
for the patients can be found in Table W1 (Supplementary Materials).
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For 14 patients, corresponding normal colonic mucosa was taken from
visually disease-free areas. Tumors were staged according to the
American Joint Cancer Committee/Union for International Cancer
Control. Status for MSI, gene mutations (within KRAS, BRAF, PIK3CA,
PTEN, and TP53), and transcriptome instability were obtained from
previous publications [26–28]. The research biobanks have been regis-
tered according to national legislation, and the study has been approved
by the Regional Committee for Medical Research Ethics (Biobank
2781; REK South-East S-09282c2009/4958). Informed consent was
obtained from patients enrolled to the study. RNA from the tissue
samples was isolated by using AllPrep DNA/RNA Mini Kit (Qiagen,
Valencia, CA). Quantity and quality were measured and evaluated as
described above. Further, a panel of 20 normal tissues from different
organs and tissue types was included (FirstChoice Human Normal
Tissue Total RNA, each has a pool of RNA from at least three indi-
viduals, with the exception of an individual sample from the stomach;
Ambion, Applied Biosystems by Life Technologies, Carlsbad, CA).
High-Throughput Paired-End RNA Sequencing
Library construction followed the standard Illumina mRNA library
preparation (icom.illumina.com, 2009; Illumina Inc, San Diego, CA),
including poly-A mRNA isolation, fragmentation, and gel-based size
selection. Shearing to about 250-bp fragments was achieved using
the Covaris S2 focused-ultrasonicator (Covaris Inc, Woburn, MA).
Sequencing was performed according to the paired-end RNA sequenc-
ing protocols from Illumina for Solexa sequencing on a Genome
Analyzer IIx with paired-end module (Illumina Inc). For all seven
cell lines, 23 to 38 million clusters were generated (Table W2; Sup-
plementary Materials). Seventy-six bps were sequenced, from each
side of a fragment about 250 bp long.
Gene Fusion Prediction and Gene Expression
Only reads marked by the Illumina pipeline (Bustard.py, OLB
1.6.0 and 1.8.0) as passed filtering were used in the analysis. We used
the fusion discovery software tool deFuse [29], version 0.2.1, with
hg19 sequence reference and Ensembl release 58 annotation data-
bases, to assist in locating potential gene fusions. Several filtering
steps of the fusions were performed. The first step included filtering
against fusions identified in normal cells and tissues. These were
identified from analysis of the Illumina Human Body Map v2 data
set, including paired-end RNA sequencing data from 16 nonmalignant
sample types, including normal colonic mucosa (ArrayExpress accession
ID E-MTAB-513 and European Nucleotide Archive study accession
ID ERP000546). The deFuse software was applied with the same
settings as for analyzing the seven colon cancer cell lines. Fusions
from the 16 cell and tissue types were pooled together and defined
as normal tissue fusions. The second filtering step removed fusions
where at least one of the fusion partners was annotated as a ribosomal
gene (as listed in Biomart Ensembl release 60, GO term 0005840).
The third step removed promiscuous fusions where one of the genes
had multiple partners within the same cell line. The fourth step
removed intrachromosomal fusions where the gene partners were
located less than 100 kbp apart. The fifth, and final, step removed
genes where the chimeric breakpoint sequences were introns or intra-
exonic, leaving only fusion transcripts with intact exon-exon boundaries,
using predominantly consensus splice sites. Gene expression levels were
computed by using Cufflinks v1.1.0 [30], with the Illumina iGenomes
Ensembl GRCh37 data set (2011-06-20) as reference, on reads aligned
with TopHat v1.3.3 [31] and Bowtie v0.12.5 [32]. Coverage and anno-
tation plots were created using R [33] and the GenomeGraphs [34]
package in Bioconductor [35].
Reverse Transcription–Polymerase Chain Reaction
and cDNA Sequencing
First-strand cDNA synthesis was performed using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster
City, CA), and reverse transcription–polymerase chain reaction
(RT-PCR) withHotStart TaqDNA Polymerase Kit (Qiagen) was per-
formed to validate the existence of the nominated fusion transcripts.
Primers were designed to span the fusion breakpoints using the Primer3
software [36] with default parameters (primer sequences are shown in
Table W3; Supplementary Materials). The PCR products were run
on a 2% agarose gel containing ethidium bromide. When only one
band was present after electrophoresis, the PCR product was cleaned
using ExoSAP-IT (GE Healthcare, Little Chalfont, United Kingdom)
before sequencing. When several bands were present, each was cut
and eluted using the MinElute Gel Extraction Kit (Qiagen). All sam-
ples were further sequenced (BigDye with ABI 3730 DNA analyzer;
Applied Biosystems).
Whole-Genome Paired-End DNA Sequencing
Whole-genome paired-end sequencing was performed by BGI
Hong Kong (Hong Kong, China) on the four cell lines with confirmed
fusion transcripts (HCT15, HCT116, HT29, and SW480) to an
average coverage of ×30. Around 850 million 100-bp paired-end reads
were produced for each cell line. The sequence reads were aligned by
BWA version 0.6.1 [37] against hg19, and the loci of the validated
fusion transcripts were visualized in the Integrative Genomics Viewer
[38]. Genomic breakpoints were identified by nFuse version 0.2.0 [39].
Fluorescence in situ Hybridization (FISH)
To detect chromosomal rearrangements involving AKAP13 and
PDE8A, we used a triple color probe FISH strategy flanking the
aforementioned genes. Bacterial artificial chromosome (BAC) clones
targeting the 5′ region of PDE8A (CTD-2253L13), the 3′ region of
AKAP13 (RP11-296P8 and CTD-3247B18), and the 200-kb region
between the two genes (CTD-2222G4) were selected using the UCSC
Human Genome Browser and obtained from the BACPAC Resources
Center (Oakland, CA). BAC DNA was extracted using the Plasmid
DNA Purification Kit (MACHEREY-NAGEL GmbH KG, Duren,
Germany) and amplified using the GenomiPhi V2 DNA Amplification
Kit (WGA kit; GEHealthcare) according to themanufacturer’s instruc-
tions. BAC DNA was labeled with SpectrumGreen (CTD-2222G4)–,
SpectrumRed (CTD-2253L13)–, and SpectrumAqua (CTD-3247B18,
RP11-296P8)–conjugated nucleotides by nick translation according
to the manufacturer’s instructions (Nick Translation DNA Labelling
System; Enzo Life Sciences, Farmingdale, NY). Adequate mapping
and probe specificity of all BAC clones was confirmed by hybridiza-
tion onto normal human metaphases. SW480metaphase spreads were
obtained according to standard procedures.
Results
Identification of Fusion Transcripts and Gene Expression
from Paired-End RNA Sequencing Data
Altogether 220 million paired-end sequence reads were generated
from seven colon cancer cell lines (Table W2; Supplementary Materials;
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European Nucleotide Archive study accession ID ERP002049). From
these, 3391 candidate fusion transcripts were identified with at least
five-fold coverage of sequence pairs across the fusion partners and
at least three individual sequence reads spanning the actual break-
point. Subsequent filtering resulted in a set of 11 fusion transcripts
reliably nominated for experimental validation (Figure 1 and TableW4,
A and B; Supplementary Materials). Briefly, first, 644 fusions were
removed, because they were also identified in a set of 16 miscel-
laneous types of normal cells and tissues by use of the same data
processing algorithm as for the cancer cell lines. The second filter re-
moved 1419 fusions where at least one of the partner genes encoded
ribosomal proteins, known to be frequent artifacts. The third filter
removed 1116 fusions in which a common partner in a number of
different fusions in the same sample was included. The fourth filter
removed 39 of the remaining chimeric sequences where the gene
partners were localized within less than 100 kb on the same chromo-
some, likely to be read-throughs. The fifth filter removed 162 addi-
tional chimeric sequences and ensured that only chimeric sequences
with exact whole exons at either side of the breakpoints were included,
preserving consensus splice sites.
Experimental Verification and Exploration within Additional
Colon Cancer Cell Lines
The presence of the 11 CRC fusion transcripts selected for experi-
mental validation were verified by RT-PCR of RNA from the same cell
lines in which they were identified, and the junction was confirmed by
Sanger sequencing (Table 1). Four of these were interchromosomal,
whereas six were intrachromosomal. For all experimentally verified
fusions, RT-PCR spanning the same exon-exon boundaries as ini-
tially identified was performed on a set of 19 colon cancer cell lines
(including the seven analyzed by RNA sequencing). For three of the
10 fusion transcripts multiple positive bands were observed (86%-
95% of cell lines; Table 2), and for these, an additional nested PCR
primer pair was designed to ensure specificity of the analysis. The three
recurrent fusion transcripts were AKAP13-PDE8A (86%; Figure 2),
COMMD10-AP3S1 (95%; Figure 3), and CTB-35F21.1-PSD2
(86%; Figure W1; Supplementary Materials). The other fusion tran-
scripts were positive in one or two cell lines each (Table W5; Supple-
mentary Materials).
The AKAP13-PDE8A locus was analyzed by three-color interphase
and metaphase FISH on the SW480 cell line, showing predominantly
five signals per cell (two in seemingly normal chromosome 15 and
three in aberrant chromosomes), but no evidence of chromosome re-
arrangement splitting signals from within or between AKAP13 and
PDE8A. However, from whole-genome sequencing data of SW480,
we found an increased coverage in the particular genomic segment
from intron 2 in PDE8A to intron 1 in AKAP13, involving the exact
set of exons corresponding to the observed AKAP13-PDE8A fusion
transcript (Figure 2B), indicating that there is a duplication of that
small genomic segment (below the resolution level of FISH analysis)
that juxtaposes exon 1 of AKAP13 5′ to exon 3 of PDE8A (Figure 2).
Theoretically, this fusion gene could also be originated by transloca-
tion or insertion between the two chromosome 15 regions, but these
two mechanisms do not generate copy number changes and they
would have been detectable by the FISH strategy we used.
Out of the additional experimentally verified fusion transcripts, a
similar increased coverage from the whole-genome sequence data for
the corresponding cell line was found for the COMMD10-AP3S1
region in the HCT116 cell line (Figure 3B).
By analyzing the whole-genome sequencing data using nFuse [39],
we identified a genomic breakpoint between the genes COMMD10
and AP3S1 and also of four additional fusion transcripts (Table 1).
We performed genomic PCR of the predicted breakpoint of the
COMMD10-AP3S1 fusion on the set of 19 colon cancer cell lines.
Only HCT116, from which both the fusion transcript and the genomic
breakpoint were originally identified, harbored this exact breakpoint.
The sequenced cell lines have also previously been karyotyped [25].
From this, we do not find cytogenetic evidence of genomic break-
points at the loci of the fusion partner genes. However, the reported
intrachromosomal fusion transcripts have also proximal loci that are
visible at the cytogenetic level.
Validation in Clinical Specimens
Altogether 106 clinical CRC specimens, 14 with corresponding
normal colonic mucosa, were analyzed for the presence of any of the
10 fusion transcripts. To ensure specificity of the products, nested
PCR primers were generated for the three with multiple bands in the
cell lines (AKAP13-PDE8A, COMMD10-AP3S1, and CTB-35F21.1-
PSD2). A PCR-on-PCR protocol was applied for the remaining seven
Figure 1. The identified fused sequences were filtered in a step-
wise manner for nomination of fusion transcripts for further exper-
imental validation.
Table 1. Fusion Transcripts Experimentally Validated by RT-PCR and Sanger Sequencing.
Fusion Gene Chromosome Bands Cell Line Distance
(kb)*
Genomic
Breakpoint†
Interchromosomal
SLC39A14-TSPAN15 8p21.3 10q22.1 HT29 N
NCOA3-SPINT1 20q12 15q13.3 HCT15 N
GRIN2B-CYP4F3 12p12 19p12.12 SW480 Y
FAM96A-STIM1 15q22.31 11p15.5 SW480 Y
Intrachromosomal
PRMT1-FLT3LG 19q13.33 19q13.33 HCT15 214 N
MGRN1-C16orf96 16p13.3 16p13.3 HCT15 134 Y
COMMD10-AP3S1 5q23.1 5q22.3 HCT116 198 Y
SPAG9-MBTD1 17q21.33 17q21.33 HCT116 298 Y
AKAP13-PDE8A 15q25.3 15q25.3 SW480 556 N
CTB-35F21.1-PSD2 5q31.2 5q31.2 SW480 160 N
*Distance is the outer distance between the two genes.
†Predicted genomic breakpoint by nFuse.
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to detect the small amount of expressed fusion transcripts. The
AKAP13-PDE8A fusion transcript, originally identified in the SW480
cell line, was positive in 19 of the 106 CRCs (18%) and as well in 4 of
the 14 normal colonic mucosa samples (29%; Tables 2 andW6).Of the
four positive normal samples, one was also positive for theCOMMD10-
AP3S1 fusion transcript, and another sample was also positive for the
CTB-35F21.1-PSD2 fusion transcript. TheCOMMD10-AP3S1 fusion
transcript, originally identified in the HCT116 cell line, was positive in
61 of the 106 CRCs (58%) and in 4 of the 14 normal colonic mucosa
samples (29%). The CTB-35F21.1-PSD2 fusion transcript, originally
identified in the SW480 cell line, was positive in 49 of the 106 CRCs
(46%) and in 2 of the 14 normal colonic mucosa samples (14%). Fur-
thermore, SPAG9-MBTD1 was positive in four cancers (4%) and one
normal sample (7%), NCOA3-SPINT1 was positive in one normal
sample (7%), and the remaining five fusion transcripts were negative
in all clinical CRC samples (Table W5; Supplementary Materials).
The identity of the fusion transcripts were further ensured by Sanger
sequencing in 36 samples, confirming the sequence in all, and the chi-
meric sequences were shown to be located precisely at known exon
boundaries in 31 of these (Table W7; Supplementary Materials).
Nested PCR on the three fusion transcripts AKAP13-PDE8A,
COMMD10-AP3S1, and CTB-35F21.1-PSD2 were performed on
20 additional normal tissues ofmiscellaneous sources. Of the 20 samples,
3, 10, and 17 were positive for the fusions AKAP13-PDE8A,
Figure 2. The AKAP13-PDE8A fusion transcript is recurrent in CRC, and the genomic locus is rearranged in the SW480 cell line.
(A) Twenty-four RNA sequence reads spanned the chimeric transcript breakpoint, passing from exon 1 of AKAP13 (ENST00000361243) to
exon3 ofPDE8A (ENST00000310298). Dark colors indicate exons that are not part of the fusion transcript. (B) Genomic viewof the rearranged
locus, from the top showing annotated exons of the fused genes (exons belonging to genes located between andwithin PDE8A andAKAP13
were removed for clarification), relative RNA expression levels, and DNA copy numbers. The two latter are based on coverage data from high-
throughput sequencing of RNA and DNA from the SW480 cell line. (C) The AKAP13-PDE8A fusion transcript was initially detected from the
SW480 cell line, but nested RT-PCR demonstrated detectable levels from 17 additional colon cancer cell lines (see Table 2 for cell line
identities). The specific breakpoints of the AKAP13-PDE8A fusion transcripts were verified by Sanger sequencing and shown to follow
the consensus splicing sites of the fusion partner genes.
Table 2. Nested PCR Performed on Two Patient Sample Series, One of Them Paired with Normals, and Cell Lines.
Fusion CRC Series 1 CRC Series 2 Normal Mucosa Series 2 Series 2, Pairs (Positive in Both Tumor and Normal) Tumors, Series 1 + 2 Cell Lines
n 92 14 14 14 106 21
AKAP13-PDE8A 15 (16%) 4 (29%) 4 (29%) 2 (14%) 19 (18%) 18 (86%)
CTB35F21.1-PSD2 41 (45%) 8 (57%) 2 (14%) 1 (7%) 49 (46%) 18 (86%)
COMMD10-AP3S1 49 (53%) 12 (86%) 4 (29%) 4 (29%) 61 (58%) 20 (95%)
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COMMD10-AP3S1, and CTB-35F21.1-PSD2, respectively (tissue
identities in Table W8).
For the three fusion transcripts with more than 10% positive
CRCs, we tested for associations with clinical parameters (stage,
MSI status, tumor location, gender, and age) and molecular data
(MSI, mutations in BRAF, KRAS, PIK3CA, and PTEN, and transcrip-
tome instability [26–28]). None of the associations were statistically
significant (data not shown).
Discussion
Here, we report three novel and highly recurrent fusion transcripts in
CRC, AKAP13-PDE8A, COMMD10-AP3S1, and CTB-35F21.1-
PSD2. Their high prevalence in CRC, as well as their presence in
a significant proportion of normal colonic mucosa samples, indicates
that they are commonly produced and most often not the result of
genomic rearrangement. All three recurrently detected fusion tran-
scripts have partner genes from the same chromosome, suggesting
a polymerase read-through mechanism. However, the switch of order
of the AKAP13-PDE8A implies that this mechanism cannot be the
sole explanation, and we see both genomic duplications, which is
evident from the SW480 cell line, and trans-splicing as other likely
mechanisms. A genomic breakpoint was identified in the COMMD10-
AP3S1 fusion in HCT116, and together with the increased coverage
between the breakpoints, this supports a genomic duplication as the
mechanism for these fusion transcripts and cell line. Further, since the
genomic PCR covering the breakpoint sequence was only positive for
this sample, the COMMD10-AP3S1 fusion transcript is not likely to
be due to a common copy number variant.
In the majority of the positive samples, the fusion transcripts were
expressed at low levels, underscored by the need for nested PCR for
detection. Originally, using regular one-step PCR, we detected the
CTB-35F21.1-PSD2 fusion transcript in the cell lines SW480 and
HCT15. Given also the precise joining of sequences at known exon
boundaries, we reason that the measured fusion transcripts are not
produced by artifacts of the laboratory protocol. However, the presence
of genomic rearrangements of AKAP13-PDE8A and COMMD10-
AP3S1 in one cancer cell line each indicates that the production of
fusion transcripts may guide the generation of genomic rearrangements,
similarly to a previous report on the fusion of JAZF1 and JJAZ1 in
endometrial stromal tumors [24]. Recently, a study showed that fusion
transcripts in healthy cells may also generate fusion proteins [21].
The predicted protein encoded by the AKAP13-PDE8A fusion
transcript includes only coding parts from the PDE8A partner and
with a truncation of 72 amino acid residues from its N terminus.
PDE8A encodes a phosphodiesterase involved in regulation of cyclic
adenosine monophosphate (cAMP) metabolism [40]. Five alternative
splicing variants have been characterized, with a conserved catalytic
domain located toward the C-terminal region, starting on amino acid
number 555, located on exon 18 [41]. This suggests that the catalytic
Figure 3. The COMMD10-AP3S1 fusion transcript is recurrent in CRC, and the genomic locus is rearranged in the HCT116 cell line.
(A) Twelve RNA sequence reads spanned the chimeric transcript breakpoint, passing from exon 4 of COMMD10 (ENST00000274458) to
exon 4 of AP3S1 (ENST00000316788). Dark colors indicate exons that are not part of the fusion transcript. (B) Genomic view of the rear-
ranged locus, from the top showing annotated exons of the fused genes (exons belonging to genes located between and within
COMMD10 and AP3S1were removed for clarification), relative RNA expression levels, and DNA copy numbers. The two latter are based
on coverage data from high-throughput sequencing of RNA and DNA from the HCT116 cell line. (C) The COMMD10-AP3S1 fusion tran-
script was initially detected from the HCT116 cell line, but nested RT-PCR demonstrated detectable levels in 19 additional colon cancer cell
lines (see Table 2 for cell line identities). The specific breakpoints of the COMMD10-AP3S1 fusion transcripts were verified by Sanger
sequencing and shown to follow the consensus splicing sites of the fusion partner genes.
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domain is still active in the predicted fusion protein encoded by the
AKAP13-PDE8A fusion transcript. Interestingly, the protein en-
coded by AKAP13 is an A-kinase anchoring protein [42]. Although
speculative, the regulation of PDE8A by the AKAP13 promoter may
alter cAMP-mediated signaling in cells harboring this fusion. As FISH
analysis of the fusion gene did not reveal large-scale structural rear-
rangements of the region containing both partner genes, the DNA
copy number increase suggests some local rearrangement, such as
duplication. Importantly, the increased coverage from the whole-
genome sequencing data in the SW480 cell line spans the exact
region corresponding to the AKAP13-PDE8A fusion transcript.
The breakpoint in the COMMD10-AP3S1 fusion transcript is be-
tween exon 5 of COMMD10 and exon 4 of AP3S1. COMMD10 is
predicted to encode a suppressor of nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) [43], whereas AP3S1 encodes
a partner of the AP-3 complex, an adapter-related complex that is
associated with the Golgi apparatus and more peripheral structures.
AP3S1 facilitates the budding of vesicles from the Golgi membrane
and may be directly involved in trafficking to lysosomes [44]. Increased
coverage in the COMMD10-AP3S1 locus from the whole-genome
sequence data on HCT116 suggests, as with the AKAP13-PDE8A
fusion, that a duplication of a segment covering both genes may have
caused the fusion and, hence, the DNA copy number change.
The predicted protein encoded by the CTB-35F21.1-PSD2 fusion
transcript includes the first three exons of CTB-35F21.1, which is
annotated as a lincRNA in the Havana database, and all coding exons
of PSD2, beginning with the start codon in exon 2. PSD2 encodes a
protein containing pleckstrin and Sec7 domains and is shown to in-
teract with PMS2 in the DNA mismatch repair complex [45].
The prevalence of the identified fusion transcripts may be even
higher than what is reported here, as we have only tested the break-
point between two exons originally identified to be involved in the
fusion, and other CRCs may have fusion transcripts between the
same genes at another exon at one or both sides of the breakpoint.
Furthermore, other CRCs may have one of the fusion partners ex-
changed for another gene.
Conclusions
We have identified three novel recurrent and seven novel private
fusion transcripts in CRC. This adds significantly to the knowledge
on chimeric transcripts in CRC and provides a new context for further
studies targeted at the usage of fusions as biomarkers or drug targets.
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Table W1. Clinical Data from the Two Patient Cohorts.
Series 1 Series 2 Combined
No. of patients 92 14 106
Age
Mean 65.3 75.4 66.6
Gender
Women 51 5 56
Men 41 9 50
Tumor localization
Colon 54 14
Rectum 38
T stage
T2 50 2 52
T3 42 11 53
T4 0 1 1
MSI status
MSI 14 6 20
MSS 77 8 85
NA 1 0 1
A total of 106 patients, from two cohorts, were used in validating the fusions. The cohorts were
enriched for patients with stage II or stage III CRC.
Table W2. Number of Paired RNA Sequence Reads that Passed the Illumina Chastity Filtering and
the Number of Reads that Aligned to the Reference Genome hg19, Using TopHat v1.3.3 and Bowtie
0.12.7, for Each of the Seven Cell Lines on the Illumina Genome Analyzer IIx Instrument.
Cell Line Filtered Clusters (M) Reads Aligned (M)
HT29 33.9 61.3
HCT15 31.3 43.8
SW480 33.5 54.6
SW48 23.4 32.6
HCT116 32.1 46.8
LS1034 31.4 34.1
RKO 37.6 61.7
Table W3. Oligonucleotide Primers Used in RT-PCR to Validate the Fusion Transcripts.
Fusion Transcript Cell Line with Indication from RNA Sequence Data Forward Primer Reverse Primer
MGRN1-C16orf96 HCT15 TGCAGGACTTGCTCACTGAT GCTGCAGTGCAACCATCTT
NCOA3-SPINT1 HCT15 TAAAGCTGAGCTGCGAGGAA GTGCACAGAAGCCACAAGG
PRMT1-FLT3LG HCT15 TACCGTCAAGGTGGAAGACC GAAGTTCTGGCGAGTGATCC
COMMD10-AP3S1 HCT116 CAGCTTTGCAGCAGCAATTA TGTGCATCAATTTGTGTAACAATC
COMMD10-AP3S1* HCT116 CAAAGCTGAAGCATTTGTCA CCCATCACCATTTCTGCAAG
COMMD10-AP3S1† HCT116 GCCACCCAGTTTTATGCTTG GCAAGACCAAGAGGTTTTGATG
SPAG9-MBTD1 HCT116 GTGCTGGAGAACCTGGACTC CCATTCCCCACTCTGGTCTA
SLC39A14-TSPAN15 HT29 CTGCCTGGACCTCCTCTTTC GGACTACCGAGATTGGAGCA
AKAP13-PDE8A SW480 GCGAAGGTGAAGAGTTGTCC AACCCTGCTTTTTCACATGC
AKAP13-PDE8A* SW480 TGTGCTCTGCCGAGACTG AGCCTGAGCCTCCTTGGTA
CTB-35F21.1-PSD2 SW480 AGAGCTCCTCACCTGTTCCA TCCTCAGGCACTGCAGATAA
CTB-35F21.1-PSD2* SW480 GTGTCTCCTGAGCCCACTCC TCACTGGCCATCCCATTC
FAM96A-STIM1 SW480 CTGGAAGTGGTCTCGGAAAG TCAGCCACTGTACCACCTCA
GRIN2B-CYP4F3 SW480 ATTCCCAACATGCTCACTCC GCATCACTCCTGGGTGTCTT
*Primers used in nested RT-PCR.
†Primers used for testing the genomic breakpoint.
Table W4. By Using Five Filtering Steps, the Number of Candidate Fusions was Reduced from 3391 to 11.
Sample Unfiltered Fusions Normal Ribosomal Promiscuous Intrachromosomal <100 kb Not Exon Boundaries
(A) The number of potential fusions in the sequenced cell lines, before and after the five filtering steps
RKO 999 880 397 45 40 1
HCT15 705 586 358 36 27 1
HCT116 693 545 207 41 31 2
SW480 506 406 220 43 37 6
LS1034 381 293 128 31 26 0
HT29 75 34 15 14 10 1
SW48 32 3 2 2 2 0
All 3391 2747 1328 212 173 11
(B) The number of potential fusions in the sequenced cell lines applying each filter separately
RKO 999 880 418 72 897 96
HCT15 705 586 390 71 635 75
HCT116 693 545 228 59 586 79
SW480 506 406 235 136 433 64
LS1034 381 293 137 55 332 42
HT29 75 34 20 35 56 14
SW48 32 3 3 6 17 6
All 3391 2747 1431 434 2956 376
Figure W1. The CTB-35F21.1-PSD2 fusion transcript is recurrent in CRC, and the genomic locus is rearranged in the SW480 cell line.
(A) Nine sequence reads spanned the chimeric breakpoint, passing from exon 3 of CTB-35F21.1 (ENST00000515296) to exon 2 of PSD2
(ENST00000274710). Dark colors indicate exons that are not part of the fusion transcript. (B) Genomic view of the rearranged locus, from
the top showing annotated exons of the fused genes (exons belonging to genes located between and within CTB-35F21.1 and PSD2were
removed for clarification) and relative RNA expression levels and DNA copy numbers, both based on high-throughput sequencing data
from the SW480 cell line. (C) The CTB-35F21.1-PSD2 fusion transcript was initially detected in the SW480 cell line, but nested RT-PCR
demonstrated detectable levels in 17 additional colon cancer cell lines. The identity of theCTB-35F21.1-PSD2 fusion transcript was verified
by Sanger sequencing.
Table W5. Number of Positive Samples for Each of the 10 Experimentally Verified Fusion Transcripts.
Fusion Transcript Colon Cancer Cell Lines Clinical CRCs Normal Colonic Mucosa
n 21 106 14
AKAP13-PDE8A 18 19 4
COMMD10-AP3S1 20 61 4
CTB-35F21.1-PSD2 18 49 2
FAM96A-STIM1 1 0 0
GRIN2B-CYP4F3 1 0 0
MGRN1-AC023830.2 2 0 0
SPAG9-MBTD1 1 4 1
NCOA3-SPINT1 2 0 1
PRMT1-FLT3LG 2 0 0
SLC39A14-TSPAN15 1 0 0
Table W8. The Presence of Fusion Transcripts in 20 Normal RNA Samples.
Sample AKAP13-PDE8A COMMD10-AP3S1 CTB-35F21.1-PSD2
Adipose N N Y
Bladder N N Y
Brain N N Y
Cervix N N Y
Colon Y Y Y
Esophagus N Y Y
Heart N N N
Kidney N N Y
Liver N Y Y
Lung Y N Y
Ovary N Y Y
Placenta N Y Y
Prostate N N Y
Skeletal muscle N N Y
Spleen N Y Y
Stomach N N N
Testes Y Y Y
Thymus N Y Y
Thyroid N Y N
Trachea N Y Y
Table W7. Sequence Validation of Nested PCR Products was Performed on Altogether 36 Samples
Positive for either of the Identified Fusion Transcripts.
Fusion Transcript Positive Samples Confirming the Identity of Both Partner Genes
COMMD10-AP3S1 7/7 (100%)
CTB-35F21.1-PSD2 6/6 (100%)
AKAP13-PDE8A 5/6 (83%)
SPAG9-MBTD1 2/4 (50%)
NCOA3-SPINT1 2/3 (67%)
PRMT1-FLT3LG 7/8 (88%)
MGRN1-C16orf96 2/2 (100%)
Table W6. The Presence of Fusion Transcripts in the 14 Matched Tumor-Normal Samples from
Series 2.
Series 2 Pair AKAP13-PDE8A CTB-35F21.1-PSD2 COMMD10-AP3S1
Tumor Normal Tumor Normal Tumor Normal
1 N N N N Y N
2 N N N N Y Y
3 N N Y Y Y N
4 N N Y N Y N
5 Y N N N N N
6 N N Y N Y N
7 N N N N Y Y
8 N N Y N Y N
9 Y Y N Y Y N
10 N N Y N Y Y
11 N Y Y N Y N
12 N N N N N N
13 N Y N N Y Y
14 Y Y Y N Y N
